MIE-101 / Mosaic ImmunoEngineering - LARVOL DELTA

Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 (Issuer Direct) - "Mosaic ImmunoEngineering...announced that the US Patent and Trademark Office (USPTO) has issued an additional patent to protect the technology behind Mosaic's lead immuno-oncology product candidate, MIE-101....Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities."

Patent • Oncology

Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform (Issuer Direct) - "Mosaic ImmunoEngineering...announced that two research grants totaling $4.3 million from the National Cancer Institute (NCI) were awarded to the Company's collaborating scientists and their respective academic institutions. The funding will be used for further studies investigating the activity of CPMV, a first-in-class plant virus used to stimulate immune responses against cancer. The Company's lead CPMV oncology candidate, MIE-101, is in late-stage preclinical development."

Financing • Oncology

Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma (Yahoo Finance) - "Mosaic ImmunoEngineering...announced a new article published in the journal 'Molecular Pharmaceuticals'....Data showed reduced tumor burden, prolonged survival, and induced tumor antigen-specific immunologic memory to prevent relapse - most importantly, systemic activity and abscopal effect was observed in a two-tumor melanoma mouse model....These results extend earlier published data demonstrating immune activation and synergistic antitumor activity utilizing wild-type CPMV (MIE-101) in combination with an OX40 agonist antibody."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor

Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation (Yahoo Finance) - "Mosaic ImmunoEngineering...announced a keynote presentation delivered on Friday, October 29, at the 'Materials in the Anthropocence' Conference in Michoacán, México....The immune-mediated anti-tumor effect is potent and durable; efficacy is observed in distant metastatic sites and animals are protected from tumor recurrence. CPMV is the core technology behind Mosaic's lead immuno-oncology candidate, MIE-101."

Preclinical • Oncology

Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference (Yahoo Finance) - “Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101. Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor immunity….Mosaic ImmunoEngineering, Inc….announced that Steven King, president and chief executive officer of Mosaic, will present at the 23rd Annual SoCalBio Conference in Long Beach, California, on Thursday, October 21 at 12:15 pm PST. Mr. King's presentation will focus on Mosaic's natural immuno-oncology candidate MIE-101, and the Company's plans to advance the candidate into clinical development.”

Clinical data • Oncology

Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101 (Issuer Direct) - “Mosaic ImmunoEngineering…announced a new preclinical publication available online in the journal Biomaterials that further expand the understanding of the antitumor potency and mechanism of action of the Company's lead immuno-oncology candidate, MIE-101, (cowpea mosaic virus, CPMV) a novel Toll-like receptor (TLR) tri-agonist…Measurements at the end of the study showed that tumors in the MIE-101-treated group that targeted TLRs 2, 4 and 7 were approximately 80% smaller as compared to tumors in the TLR 2 and 4-targeted group and in the TLR 7-targeted group. Additionally, MIE-101 treated tumors were approximately 70% smaller than tumors treated with a combination of agents (eCPMV+R848) that collectively target the same three TLRs...'We look forward to additional updates as we prepare for discussions with regulatory agencies with the goal of filing an Investigational New Drug (IND) or similar application in 2022."

IND • Preclinical • Oncology • Solid Tumor